BIOA
What one share of Bioage Labs holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
Bioage Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.26 |
|---|---|
| Profit | −$2.37 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.21 |
| Cash and investments | $8.33 |
| Debt | $0.01 |
| Book value | $8.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$38.17 | $0.10 | −$22.43 | — | −$103.62 |
| 2024 | $0.00 | −$6.63 | $0.03 | −$4.84 | — | — |
| 2025 | $0.25 | −$2.24 | $0.02 | −$2.29 | — | $7.28 |